Akihiro Murakami
Papers
1
Total Citations
4
H-Index
1
About
Dr. Akihiro Murakami is a clinical researcher whose work focuses on the chemopreventive and therapeutic potential of natural compounds, particularly flavonoids, in oncology. His primary research area is prostate cancer, with a specific emphasis on developing effective, low-toxicity interventions for patients under active surveillance. Dr. Murakami’s major contribution is his pioneering investigation into luteolin, a dietary flavonoid, as a chemotherapeutic agent for prostate cancer. His most cited paper, "Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance" (2025, 4 citations), provides foundational clinical data addressing the critical need for treatments that can delay or prevent disease progression without the side effects of androgen deprivation therapy. This work builds on his earlier preclinical studies demonstrating luteolin’s chemopreventive potential, bridging the gap between laboratory findings and clinical application. Though early in its citation history, this study represents a significant step toward integrating natural compounds into standard prostate cancer management. Dr. Murakami’s research offers hope for patients seeking safer, effective options, highlighting his commitment to translational medicine and patient-centered outcomes.
Research Focus
Key Achievements
Top Papers
- 1